IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 Study - IGC Pharma, INC.

Press

Releases

September 19, 2019

IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 Study

Related Posts

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research

February 26, 2026

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

February 23, 2026

CEO Update

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research

February 26, 2026

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026